文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

一种新型致癌基因,富含亮氨酸重复序列蛋白1,介导缺氧诱导的肝细胞癌进展。

A novel oncogene, leucine-rich repeat protein 1, mediates hypoxia-induced hepatocellular carcinoma progression.

作者信息

Tao Li, Guo Yixian, Liu Runkun, Lv Meng, Wang Yufeng

机构信息

Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China.

出版信息

Funct Integr Genomics. 2025 Jun 3;25(1):117. doi: 10.1007/s10142-025-01626-w.


DOI:10.1007/s10142-025-01626-w
PMID:40459634
Abstract

The involvement of leucine rich repeats protein 1 (LRR1) in various biological processes has been established, but its specific role and potential mechanisms in hepatocellular carcinoma (HCC) remain unclear. The aim of this study was to explore the potential expression, function, and mechanisms of LRR1 in HCC. Data acquired from TCGA, GEO and other online databases was used to investigate the expression and roles of LRR1 in HCC through various approaches, including expression profiling, clinical significance analysis, methylation status examination, immune infiltration assessment, genomic mutation analysis, and pathway network exploration. With findings in bioinformatic analysis, we further validated the involvement of LRR1 in HCC progression by cellular experiments. The expression of LRR1 is significantly upregulated in HCC compared to normal liver tissues and cell line. Additionally, the involvement of LRR1 was implicated in various modifications across diverse aspects associated with HCC. Enrichment analysis indicated that LRR1 was induced by hypoxia in HIF-1-dependent manner. The cell experiments convincingly demonstrated the pivotal role of LRR1 in tumor cell proliferation, migration, invasion and angiogenesis under the regulation of HIF-1. Our findings demonstrate a novel oncogene LRR1 in HCC, which is also a HIF-1 target gene and functions as a promising biomarker and contributes to the hypoxia-induced progression of HCC through a HIF-1/LRR1 manner.

摘要

富含亮氨酸重复序列蛋白1(LRR1)参与多种生物学过程已得到证实,但其在肝细胞癌(HCC)中的具体作用和潜在机制仍不清楚。本研究旨在探讨LRR1在HCC中的潜在表达、功能及机制。利用从TCGA、GEO和其他在线数据库获取的数据,通过多种方法研究LRR1在HCC中的表达和作用,包括表达谱分析、临床意义分析、甲基化状态检测、免疫浸润评估、基因组突变分析和通路网络探索。基于生物信息学分析结果,我们通过细胞实验进一步验证了LRR1参与HCC进展。与正常肝组织和细胞系相比,LRR1在HCC中的表达显著上调。此外,LRR1参与了与HCC相关的各个方面的多种修饰。富集分析表明,LRR1在缺氧条件下以HIF-1依赖的方式被诱导。细胞实验令人信服地证明了LRR1在HIF-1调控下对肿瘤细胞增殖、迁移、侵袭和血管生成的关键作用。我们的研究结果表明,LRR1是HCC中的一种新型癌基因,也是一种HIF-1靶基因,并作为一种有前景的生物标志物发挥作用,通过HIF-1/LRR1方式促进HCC的缺氧诱导进展。

相似文献

[1]
A novel oncogene, leucine-rich repeat protein 1, mediates hypoxia-induced hepatocellular carcinoma progression.

Funct Integr Genomics. 2025-6-3

[2]
HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.

J Exp Clin Cancer Res. 2017-4-27

[3]
regulates angiogenesis and tumor progression in hepatocellular carcinoma via the HIF-1α/VEGF pathway.

Biomol Biomed. 2024-12-11

[4]
Long non-coding RNA PAARH promotes hepatocellular carcinoma progression and angiogenesis via upregulating HOTTIP and activating HIF-1α/VEGF signaling.

Cell Death Dis. 2022-2-2

[5]
Mild chronic hypoxia-induced HIF-2α interacts with c-MYC through competition with HIF-1α to induce hepatocellular carcinoma cell proliferation.

Cell Oncol (Dordr). 2021-10

[6]
Hypoxia-induced TRPM7 promotes glycolytic metabolism and progression in hepatocellular carcinoma.

Eur J Pharmacol. 2024-7-5

[7]
HIF-1α-activated TM4SF1-AS1 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by enhancing TM4SF1 expression.

Biochem Biophys Res Commun. 2021-8-20

[8]
The role of Aurora A in hypoxia-inducible factor 1α-promoting malignant phenotypes of hepatocelluar carcinoma.

Cell Cycle. 2013-8-7

[9]
Long non-coding RNA MAPKAPK5-AS1/PLAGL2/HIF-1α signaling loop promotes hepatocellular carcinoma progression.

J Exp Clin Cancer Res. 2021-2-17

[10]
LYRM2 Promotes the Growth and Metastasis of Hepatocellular Carcinoma via Enhancing HIF-1α-Dependent Glucose Metabolic Reprogramming.

J Cell Mol Med. 2024-12

本文引用的文献

[1]
Reply.

Gastroenterology. 2025-5-2

[2]
Precision treatment in advanced hepatocellular carcinoma.

Cancer Cell. 2024-2-12

[3]
Investigation of GPR143 as a promising novel marker for the progression of skin cutaneous melanoma through bioinformatic analyses and cell experiments.

Apoptosis. 2024-4

[4]
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy.

Nat Rev Clin Oncol. 2023-12

[5]
Myelination- and migration-associated genes are downregulated after phagocytosis in cultured oligodendrocyte precursor cells.

J Neurochem. 2023-11

[6]
Tumour-infiltrating lymphocytes: from prognosis to treatment selection.

Br J Cancer. 2023-2

[7]
The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest.

Nucleic Acids Res. 2023-1-6

[8]
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma.

Hepatology. 2023-5-1

[9]
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients.

J Hematol Oncol. 2022-5-18

[10]
Hypoxia inducible lncRNA-CBSLR modulates ferroptosis through m6A-YTHDF2-dependent modulation of CBS in gastric cancer.

J Adv Res. 2022-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索